Press release
Endometriosis Pipeline 2024: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | Organon, Ironwood Pharma, AbbVie/Neurocrine Biosciences, Mitsubishi Tanabe Pharma Corporation
The Endometriosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Endometriosis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Endometriosis Market.
Some of the key takeaways from the Endometriosis Pipeline Report: https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Endometriosis treatment therapies with a considerable amount of success over the years.
• Endometriosis companies working in the treatment market are Nanjing Chia-tai Tianqing Pharmaceutical, Hera Biotech, Inc., Bio Genuine (Shanghai) Biotech Co., Ltd., Sumitomo Pharma Switzerland GmbH, Organon, Ironwood Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, AbbVie/Neurocrine Biosciences, ObsEva/Kissei Pharmaceuticals, SWK/Enteris BioPharma, Bayer/Hope Medicine, Tiumbio, and others, are developing therapies for the Endometriosis treatment
• Emerging Endometriosis therapies in the different phases of clinical trials are- Elagolix, MetriDx, BG2109, Relugolix Combination Tablet, FOR 6219, IW-3300, MT-2990, ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109), OVAREST (leuprorelin oral), HMI-115, TU2670 (NCE-403), OG-6219, and others are expected to have a significant impact on the Endometriosis market in the coming years.
• In October 2024, Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing innovative treatments for advanced solid tumors and other serious diseases, has announced a sponsored research agreement with the University of Cincinnati. The agreement will explore the use of Lisata's novel cyclic peptide product, certepetide, in combination with bevacizumab (a VEGF inhibitor) in a preclinical animal model for treating endometriosis. While bevacizumab has shown efficacy in treating endometriosis, its high dosage levels can cause systemic side effects, limiting its use in otherwise healthy young women. Lisata will provide funding and certepetide for the research conducted by the University of Cincinnati.
• In March 2024, By the end of this year, Gynica, headquartered in Israel, plans to administer the first dose to a patient in a Phase I trial evaluating its cannabioid-based treatments, IntraVagS301 and IntraVagS302, for endometriosis.
Endometriosis Overview
Endometriosis is a condition where tissue similar to the lining of the uterus (endometrium) grows outside the uterus, often on the ovaries, fallopian tubes, and pelvic tissue. This tissue behaves like the uterine lining, thickening, breaking down, and bleeding with each menstrual cycle, but it has no way to exit the body, leading to inflammation, pain, and sometimes infertility. Common symptoms include pelvic pain, heavy menstrual bleeding, and pain during intercourse or bowel movements. The exact cause is unknown, but factors like genetics, immune system disorders, or hormonal imbalances may contribute. Treatment options include pain management, hormonal therapy, and surgery.
Get a Free Sample PDF Report to know more about Endometriosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Endometriosis Drugs Under Different Phases of Clinical Development Include:
• Elagolix: Nanjing Chia-tai Tianqing Pharmaceutical
• MetriDx: Hera Biotech, Inc.
• BG2109: Bio Genuine (Shanghai) Biotech Co., Ltd.
• Relugolix Combination Tablet: Sumitomo Pharma Switzerland GmbH
• FOR 6219: Organon
• IW-3300: Ironwood Pharmaceuticals
• MT-2990: Mitsubishi Tanabe Pharma Corporation
• ORIAHNN (elagolix/estradiol/norethindrone acetate): AbbVie/Neurocrine Biosciences
• Linzagolix (OBE2109): ObsEva/Kissei Pharmaceuticals
• OVAREST (leuprorelin oral): SWK/Enteris BioPharma
• HMI-115: Bayer/Hope Medicine
• TU2670 (NCE-403): Tiumbio
• OG-6219: Organon
• Quinagolide: Ferring Pharmaceuticals
• Linzagolix: ObsEva
Endometriosis Route of Administration
Endometriosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
Endometriosis Molecule Type
Endometriosis Products have been categorized under various Molecule types, such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
Endometriosis Pipeline Therapeutics Assessment
• Endometriosis Assessment by Product Type
• Endometriosis By Stage and Product Type
• Endometriosis Assessment by Route of Administration
• Endometriosis By Stage and Route of Administration
• Endometriosis Assessment by Molecule Type
• Endometriosis by Stage and Molecule Type
DelveInsight's Endometriosis Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Endometriosis product details are provided in the report. Download the Endometriosis pipeline report to learn more about the emerging Endometriosis therapies
https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Endometriosis Therapeutics Market include:
Key companies developing therapies for Endometriosis are - AbbVie, Neurocrine Biosciences, Kissei Pharmaceuticals, SWK, Enteris BioPharma, Bayer, Hope Medicine, Tiumbio, Organon, Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, TiumBio Co., Ltd., Mitsubishi Tanabe Pharma, and others.
Endometriosis Pipeline Analysis:
The Endometriosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Endometriosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Endometriosis Treatment.
• Endometriosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Endometriosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Endometriosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Endometriosis drugs and therapies
https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Endometriosis Pipeline Market Drivers
• The development of drug delivery systems represents a new approach in pain treatment among endometriosis patients, extensive research on Non-steroidal anti-inflammatory drugs are some of the important factors that are fueling the Endometriosis Market.
Endometriosis Pipeline Market Barriers
• However, less robust pipeline, high cost of treatment procedures and other factors are creating obstacles in the Endometriosis Market growth.
Scope of Endometriosis Pipeline Drug Insight
• Coverage: Global
• Key Endometriosis Companies: Nanjing Chia-tai Tianqing Pharmaceutical, Hera Biotech, Inc., Bio Genuine (Shanghai) Biotech Co., Ltd., Sumitomo Pharma Switzerland GmbH, Organon, Ironwood Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, AbbVie/Neurocrine Biosciences, ObsEva/Kissei Pharmaceuticals, SWK/Enteris BioPharma, Bayer/Hope Medicine, Tiumbio, and others
• Key Endometriosis Therapies: Elagolix, MetriDx, BG2109, Relugolix Combination Tablet, FOR 6219, IW-3300, MT-2990, ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109), OVAREST (leuprorelin oral), HMI-115, TU2670 (NCE-403), OG-6219, and others
• Endometriosis Therapeutic Assessment: Endometriosis current marketed and Endometriosis emerging therapies
• Endometriosis Market Dynamics: Endometriosis market drivers and Endometriosis market barriers
Request for Sample PDF Report for Endometriosis Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Endometriosis Report Introduction
2. Endometriosis Executive Summary
3. Endometriosis Overview
4. Endometriosis- Analytical Perspective In-depth Commercial Assessment
5. Endometriosis Pipeline Therapeutics
6. Endometriosis Late Stage Products (Phase II/III)
7. Endometriosis Mid Stage Products (Phase II)
8. Endometriosis Early Stage Products (Phase I)
9. Endometriosis Preclinical Stage Products
10. Endometriosis Therapeutics Assessment
11. Endometriosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Endometriosis Key Companies
14. Endometriosis Key Products
15. Endometriosis Unmet Needs
16 . Endometriosis Market Drivers and Barriers
17. Endometriosis Future Perspectives and Conclusion
18. Endometriosis Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Endometriosis Market https://www.delveinsight.com/report-store/endometriosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Endometriosis Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Latest Reports:
• Transdermal Drug Delivery Devices: https://www.delveinsight.com/report-store/transdermal-drug-delivery-devices-market
• Infusion Pumps Market: https://www.delveinsight.com/report-store/infusion-pumps-market
• Acute Radiation Syndrome Market: https://www.delveinsight.com/report-store/acute-radiation-syndrome-pipeline-insight
• Human Papillomavirus Hpv Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Endometriosis Pipeline 2024: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | Organon, Ironwood Pharma, AbbVie/Neurocrine Biosciences, Mitsubishi Tanabe Pharma Corporation here
News-ID: 3818921 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Endometriosis
Endometriosis Pain Market Massive Growth opportunity Ahead
Introduction
Endometriosis is a chronic, estrogen-dependent condition in which endometrial-like tissue grows outside the uterus, leading to inflammation, scarring, and adhesions. One of its most debilitating symptoms is pelvic pain, often accompanied by painful periods, infertility, and fatigue. Globally, endometriosis affects an estimated 10% of women of reproductive age, making it a major public health concern.
Despite its prevalence, endometriosis pain has historically been underdiagnosed and undertreated. Patients often face diagnostic delays…
Hope for Rapid, Non-Invasive Endometriosis Diagnosis
New diagnostic test for endometriosis, the ENDOSURE test, offers decision support to clinicians with 99.87% accurate results in less than an hour, could transform women's healthcare
EDMONTON, AB - In a groundbreaking development for women's health featured on Global News Calgary by journalist Jayme Doll on March 12, 2025, the ENDOSURE test emerges as a beacon of hope for millions suffering from undiagnosed endometriosis in. This non-invasive diagnostic tool promises to…
Emerging Endometriosis Market Trend 2025-2034: Innovative Medications Reshaping …
"How Is the Endometriosis Market Projected to Grow, and What Is Its Market Size?
The endometriosis market has seen rapid growth in recent years. It is expected to grow from $1.4 billion in 2024 to $1.55 billion in 2025, at a compound annual growth rate (CAGR) of 10.2%. The growth can be attributed to delayed diagnosis, increased awareness, advances in laparoscopic surgery, hormonal therapies, and the support of patient advocacy groups.
The…
Endometriosis Treatment Market Analysis, Size, Share & Trends | 2031
In recent years, the global Endometriosis Treatment Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Endometriosis Treatment Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including Porters Five…
Endometriosis Market Size, Share, Insight, Treatment 2024-2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Endometriosis Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $2.01 billion In 2028 At A…
Endometriosis Market Trends, Size, Forecast - 2018-2023
Endometriosis is a painful disorder in which the layer of tissue that normally surfaces inside the uterus, starts growing outside the uterus. This mainly occurs on the fallopian tubes, ovaries, and tissue around the uterus; however, in exceptional cases it may occur in other parts of the body. The endometriosis leads to various physical symptoms such as severe menstrual cramps, nausea and vomiting, fatigue, diarrhea, constipation, long-term pelvic pain, and…
